EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Selective MAP3K1 Inhibitor Facilitates Discovery of NPM1 as a Member of the Network

Lidia Boghean iD, Sarbjit Singh iD, Kiran K Mangalaparthi iD, Smitha Kizhake, Lelisse Umeta, Donn Wishka, Paul Grothaus, Akhilesh Pandey iD, Amarnath Natarajan iD

Molecules · 30.04.2025 · 30 (9) · 2001

DOI: 10.3390/molecules30092001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 30.04.2025. Verfasst von Lidia Boghean und 8 weiteren Autor:innen. Beteiligte Einrichtung: Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Nuclear Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The quinoxaline core is found in several biologically active compounds, with Erdafitinib being the first FDA-approved quinoxaline derivative that targets a kinase and exhibits anti-cancer properties. We previously reported a quinoxaline analog (84) that displayed anti-cancer effects by inhibiting IKKβ, a key kinase in the NFκB pathway. Here, we present the synthesis of a regioisomer (51-106) and its characterization as a selective MAP3K1 inhibitor with improved metabolic stability and oral bioavailability. We used the small molecule MAP3K1 inhibitor in a proteomics study that identified NPM1 as a member of the MAP3K1 network.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsNuclear ProteinsNucleophosminHumansAnimalsQuinoxalinesProteomics

Stichwörter der Autor:innen

MAP3K1 inhibitorNPM1phosphoproteomicsquinoxaline

Substanzen

NucleophosminNPM1 protein, humanProtein Kinase InhibitorsNuclear ProteinsQuinoxalines

Autor:innen und Institutionen

  • Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Department of Laboratory Medicine and Pathology, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Drug Synthesis and Chemistry Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  • Department of Community Medicine, Manipal Academy of Higher Education, Manipal 576104, India.
  • Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.

ORCID-Profile: Lidia Boghean, Sarbjit Singh, Kiran K Mangalaparthi, Akhilesh Pandey, Amarnath Natarajan

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIH

Zitieren

APA

Boghean, L., Singh, S., Mangalaparthi, K. K., Kizhake, S., Umeta, L., Wishka, D., Grothaus, P., Pandey, A., & Natarajan, A. (2025). A Selective MAP3K1 Inhibitor Facilitates Discovery of NPM1 as a Member of the Network. Molecules, 30(9), 2001. https://doi.org/10.3390/molecules30092001

Vancouver

Boghean L, Singh S, Mangalaparthi KK, Kizhake S, Umeta L, Wishka D, et al. A Selective MAP3K1 Inhibitor Facilitates Discovery of NPM1 as a Member of the Network. Molecules. 2025;30(9):2001. doi:10.3390/molecules30092001

BibTeX
@article{Boghean2025,
  author = {Boghean, Lidia and Singh, Sarbjit and Mangalaparthi, Kiran K and Kizhake, Smitha and Umeta, Lelisse and Wishka, Donn and Grothaus, Paul and Pandey, Akhilesh and Natarajan, Amarnath},
  title = {A Selective MAP3K1 Inhibitor Facilitates Discovery of NPM1 as a Member of the Network},
  journal = {Molecules},
  year = {2025},
  volume = {30},
  number = {9},
  pages = {2001},
  doi = {10.3390/molecules30092001}
}
Kostenlos starten →